While AI were associated with improved outcomes compared to tamoxifen, their use as monotherapy or even in combination with CDK4/6 inhibitors for the treatment of recurrent, advanced ER+ breast cancer is limited by acquired resistance, mainly due to ESR1 mutations. This evidence concerns the gene ESR1 and breast cancer.